You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
苑東生物(688513.SH):自主研發的1類生物藥EP-9001A注射液已完成用於骨轉移癌痛的Ib期臨牀試驗
格隆匯 04-15 16:37

格隆匯4月15日丨苑東生物(688513.SH)公佈,公司全資子公司成都優洛生物科技有限公司自主研發的1類生物藥EP-9001A注射液已完成用於骨轉移癌痛的Ib期臨牀試驗並取得初步的統計分析結果。

EP-9001A注射液爲公司自主研發的治療用生物製品1類新藥,是一種全新作用機制的人源化單克隆抗體藥物,靶點爲人神經生長因子(NGF)。其作用機制爲通過選擇性靶向結合並抑制NGF,阻止來自肌肉、皮膚和器官的疼痛信號進入脊髓和大腦,具有與阿片類藥物、非甾體類抗炎藥等其他鎮痛藥不同的作用機制。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account